IMRX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 10:13):

Stats
Today's Volume	106 373
Average Volume	708 809
Market Cap	41.88M
EPS	$0 ( 2024-03-04 )
Next earnings date	( $-0.450 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.760
ATR14	$0.0180 (1.25%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Cormorant Asset Management, Lp	Sell	100	Class A Common Stock
2024-04-01	Cormorant Asset Management, Lp	Sell	300	Class A Common Stock
2024-04-01	Cormorant Asset Management, Lp	Sell	100	Class A Common Stock
2024-04-01	Cormorant Asset Management, Lp	Sell	600	Class A Common Stock
2024-04-01	Cormorant Asset Management, Lp	Sell	10	Class A Common Stock

INSIDER POWER
6.74
Last 92 transactions
Buy: 3 241 516 \| Sell: 1 367 921

Volume Correlation

Long: -0.41 (neutral)

Short: 0.04 (neutral)

Signal:(50.109) Neutral

Immuneering Corporation Correlation

10 Most Positive Correlations
PAIC	0.952
SVAC	0.945
TIL	0.941
BLPH	0.933
FTOC	0.932
TFFP	0.929
LNSR	0.928
SVOK	0.927
FTOCU	0.927
NRBO	0.921

10 Most Negative Correlations
NETE	-0.972
MMAC	-0.953
SASR	-0.949
STIM	-0.943
BSRR	-0.942
HMST	-0.94
ISTR	-0.939
FNCB	-0.939
IART	-0.939
BOCH	-0.934

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Immuneering Corporation Correlation - Currency/Commodity

-0.58
( weak negative )

-0.64
( weak negative )

0.00
( neutral )

0.49
( neutral )

0.59
( weak )

0.37
( neutral )

Immuneering Corporation Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-764 138 (0.00 %)
EPS:	$-1.880

Q4	2023
Revenue:	$0
Gross Profit:	$-185 216 (0.00 %)
EPS:	$-0.520

Q3	2023
Revenue:	$0
Gross Profit:	$-195 784 (0.00 %)
EPS:	$-0.430

Q2	2023
Revenue:	$94.42M
Gross Profit:	$94.23M (99.80 %)
EPS:	$-0.430

Financial Reports:

No articles found.

Immuneering Corporation

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.